Lantheus (NASDAQ:LNTH – Get Free Report)‘s stock had its “buy” rating restated by analysts at Truist Financial in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $125.00 price objective on the medical equipment provider’s stock. Truist Financial’s target price would suggest a potential upside of 91.19% from the stock’s previous close.
Other research analysts have also recently issued reports about the company. TheStreet upgraded Lantheus from a “c” rating to a “b-” rating in a research note on Wednesday, August 9th. StockNews.com assumed coverage on Lantheus in a report on Thursday, August 17th. They issued a “buy” rating for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $121.83.
Check Out Our Latest Stock Analysis on Lantheus
Lantheus Trading Down 1.5 %
Shares of Lantheus stock traded down $0.98 during trading on Friday, hitting $65.38. 614,294 shares of the company were exchanged, compared to its average volume of 1,008,912. The company has a debt-to-equity ratio of 1.01, a current ratio of 4.88 and a quick ratio of 4.55. The firm’s fifty day moving average price is $74.33 and its 200 day moving average price is $81.84. Lantheus has a 1-year low of $47.46 and a 1-year high of $100.85. The firm has a market capitalization of $4.47 billion, a P/E ratio of 159.46 and a beta of 0.68.
Lantheus (NASDAQ:LNTH – Get Free Report) last posted its quarterly earnings data on Thursday, August 3rd. The medical equipment provider reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.17. Lantheus had a return on equity of 67.18% and a net margin of 2.97%. The company had revenue of $321.70 million during the quarter, compared to analyst estimates of $306.48 million. As a group, sell-side analysts expect that Lantheus will post 5.19 earnings per share for the current fiscal year.
Insider Transactions at Lantheus
In other news, CAO Andrea Sabens sold 1,752 shares of the company’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total transaction of $159,204.24. Following the transaction, the chief accounting officer now owns 59,767 shares of the company’s stock, valued at $5,431,027.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CAO Andrea Sabens sold 1,752 shares of Lantheus stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total transaction of $159,204.24. Following the completion of the sale, the chief accounting officer now owns 59,767 shares in the company, valued at approximately $5,431,027.29. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Mary Anne Heino sold 10,950 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $68.58, for a total value of $750,951.00. Following the transaction, the chief executive officer now owns 329,467 shares of the company’s stock, valued at $22,594,846.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,315 shares of company stock valued at $1,353,773. Insiders own 1.50% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prosperity Financial Group Inc. lifted its holdings in shares of Lantheus by 6.9% in the second quarter. Prosperity Financial Group Inc. now owns 2,794 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 180 shares during the period. Portside Wealth Group LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth $5,442,000. Virginia Retirement Systems ET AL acquired a new stake in shares of Lantheus in the second quarter valued at about $948,000. Comerica Bank bought a new position in shares of Lantheus in the second quarter valued at approximately $63,740,000. Finally, BOKF NA lifted its position in shares of Lantheus by 127,750.0% during the second quarter. BOKF NA now owns 12,785 shares of the medical equipment provider’s stock worth $1,073,000 after acquiring an additional 12,775 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.
Lantheus Company Profile
(Get Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lantheus, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Lantheus wasn’t on the list.
While Lantheus currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Source: marketbeat.com
Lantheus (NASDAQ:LNTH – Get Free Report)‘s stock had its “buy” rating restated by analysts at Truist Financial in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $125.00 price objective on the medical equipment provider’s stock. Truist Financial’s target price would suggest a potential upside of 91.19% from the stock’s previous close.
Other research analysts have also recently issued reports about the company. TheStreet upgraded Lantheus from a “c” rating to a “b-” rating in a research note on Wednesday, August 9th. StockNews.com assumed coverage on Lantheus in a report on Thursday, August 17th. They issued a “buy” rating for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $121.83.
Check Out Our Latest Stock Analysis on Lantheus
Lantheus Trading Down 1.5 %
Shares of Lantheus stock traded down $0.98 during trading on Friday, hitting $65.38. 614,294 shares of the company were exchanged, compared to its average volume of 1,008,912. The company has a debt-to-equity ratio of 1.01, a current ratio of 4.88 and a quick ratio of 4.55. The firm’s fifty day moving average price is $74.33 and its 200 day moving average price is $81.84. Lantheus has a 1-year low of $47.46 and a 1-year high of $100.85. The firm has a market capitalization of $4.47 billion, a P/E ratio of 159.46 and a beta of 0.68.
Lantheus (NASDAQ:LNTH – Get Free Report) last posted its quarterly earnings data on Thursday, August 3rd. The medical equipment provider reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.17. Lantheus had a return on equity of 67.18% and a net margin of 2.97%. The company had revenue of $321.70 million during the quarter, compared to analyst estimates of $306.48 million. As a group, sell-side analysts expect that Lantheus will post 5.19 earnings per share for the current fiscal year.
Insider Transactions at Lantheus
In other news, CAO Andrea Sabens sold 1,752 shares of the company’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total transaction of $159,204.24. Following the transaction, the chief accounting officer now owns 59,767 shares of the company’s stock, valued at $5,431,027.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CAO Andrea Sabens sold 1,752 shares of Lantheus stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total transaction of $159,204.24. Following the completion of the sale, the chief accounting officer now owns 59,767 shares in the company, valued at approximately $5,431,027.29. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Mary Anne Heino sold 10,950 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $68.58, for a total value of $750,951.00. Following the transaction, the chief executive officer now owns 329,467 shares of the company’s stock, valued at $22,594,846.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,315 shares of company stock valued at $1,353,773. Insiders own 1.50% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prosperity Financial Group Inc. lifted its holdings in shares of Lantheus by 6.9% in the second quarter. Prosperity Financial Group Inc. now owns 2,794 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 180 shares during the period. Portside Wealth Group LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth $5,442,000. Virginia Retirement Systems ET AL acquired a new stake in shares of Lantheus in the second quarter valued at about $948,000. Comerica Bank bought a new position in shares of Lantheus in the second quarter valued at approximately $63,740,000. Finally, BOKF NA lifted its position in shares of Lantheus by 127,750.0% during the second quarter. BOKF NA now owns 12,785 shares of the medical equipment provider’s stock worth $1,073,000 after acquiring an additional 12,775 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.
Lantheus Company Profile
(Get Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lantheus, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Lantheus wasn’t on the list.
While Lantheus currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Source: marketbeat.com
